- Record: found
- Abstract: not found
- Article: not found
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Sebastian Grosicki ,
Maryana Simonova ,
Ivan Spicka ,
Ludek Pour ,
Iryrna Kriachok ,
Maria Gavriatopoulou ,
Halyna Pylypenko ,
Holger W Auner ,
Xavier Leleu ,
Vadim Doronin ,
Ganna Usenko ,
Nizar J Bahlis ,
Roman Hajek ,
Reuben Benjamin ,
Tuphan K Dolai ,
Dinesh K Sinha ,
Christopher P Venner ,
Mamta Garg ,
Mercedes Gironella ,
Artur Jurczyszyn ,
Pawel Robak ,
Monica Galli ,
Craig Wallington-Beddoe ,
Atanas Radinoff ,
Galina Salogub ,
Don A Stevens ,
Supratik Basu ,
Anna M Liberati ,
Hang Quach ,
Vesselina S Goranova-Marinova ,
Jelena Bila ,
Eirini Katodritou ,
Hanna Oliynyk ,
Sybiryna Korenkova ,
Jeevan Kumar ,
Sundar Jagannath ,
Phillipe Moreau ,
Moshe Levy ,
Darrell White ,
Moshe E Gatt ,
Thierry Facon ,
Maria V Mateos ,
Michele Cavo ,
Donna Reece ,
Larry D Anderson ,
Jean-Richard Saint-Martin ,
Jacqueline Jeha ,
Anita A Joshi ,
Yi Chai ,
Lingling Li ,
Vishnuvardhan Peddagali ,
Melina Arazy ,
Jatin Shah ,
Sharon Shacham ,
Michael G Kauffman ,
Meletios A Dimopoulos ,
Paul G Richardson ,
Sosana Delimpasi
November 2020
November 2020
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d5434185e907">Selinexor combined with dexamethasone has shown
activity in patients with heavily
pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor
with bortezomib (a proteasome inhibitor) and dexamethasone induced high response rates
with low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib.
We aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone
versus standard bortezomib and dexamethasone in patients with previously treated multiple
myeloma.
</p>